Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023.

Eight cases of locally acquired, mosquito-transmitted (i.e., autochthonous) Plasmodium vivax malaria, which has not been reported in the United States since 2003, were reported to CDC from state health departments in Florida and Texas during May 18-July 17, 2023. As of August 4, 2023, case surveillance, mosquito surveillance and control activities, and public outreach and education activities continue in both states. U.S. clinicians need to consider a malaria diagnosis in patients with unexplained fever, especially in areas where autochthonous malaria has been recently reported, although the risk for autochthonous malaria in the United States remains very low. Prompt diagnosis and treatment of malaria can prevent severe disease or death and limit ongoing transmission to local Anopheles mosquitoes and other persons. Preventing mosquito bites and controlling mosquitoes at home can prevent mosquitoborne diseases, including malaria. Before traveling internationally to areas with endemic malaria, travelers should consult with a health care provider regarding recommended malaria prevention measures, including potentially taking malaria prophylaxis. Malaria is a nationally notifiable disease; continued reporting of malaria cases to jurisdictional health departments and CDC will also help ensure robust surveillance to detect and prevent autochthonous malaria in the United States.

COMPARATIVE LABORATORY ACTIVITY AND SEMI-FIELD EFFICACY OF OMNIPRENE® G AND ALTOSID® PELLETS AGAINST AEDES AEGYPTI.

Mosquito larval control by biorational larvicides plays a crucial role in mosquito and mosquito-borne disease management. However, the availability of larvicides that meet the criteria of efficacy, safety, and quality is limited and conventional pesticides are no longer preferred for larval control. Although efforts are made to research new active ingredients (AIs), it is equally important to innovate new formulations based on currently available AIs such as microbial agents and insect growth regulators. Studies were therefore conducted to compare the laboratory activity and semi-field efficacy of OmniPrene® G and Altosid® Pellets with DR-tech, both containing 4.25% S-methoprene, at 2.8 kg/ha and 11.2 kg/ha against the yellow fever mosquito Aedes aegypti (L.) in outdoor microcosms. Both products performed equally in bioassays against the test species with comparable inhibition of emergence activities. In the semi-field study, the lower dose of Altosid Pellets at 2.8 kg/ha, showed lower efficacy than OmniPrene G during the initial 6 weeks; this difference became negligible on week 7, followed by higher efficacy in Altosid Pellets on weeks 8 and 9. More uniform efficacy was observed at the higher dose of 11.2 kg/ha. Equal performance was revealed during weeks 2 to 6, with the OmniPrene G outperforming the Altosid Pellets in week 1, but the opposite during weeks 7 to 9. Mortality patterns were similar in both products, i.e., majority of mortality occurred before emergence, although more incomplete emergence was noted in lower doses, particularly in Altosid Pellets. Overall, newly available OmniPrene G provided comparable activity and efficacy with Altosid Pellets against the test species, with the advantages of fast initial AI release and even coverage, particularly when applied at low doses.